Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Other Non-Current Assets (2021 - 2025)

Prime Medicine (PRME) has disclosed Other Non-Current Assets for 5 consecutive years, with $13.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 2.64% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Sep 2025, down 2.64%, and an annual FY2024 reading of $14.1 million, up 1705.13% over the prior year.
  • Other Non-Current Assets was $13.7 million for Q3 2025 at Prime Medicine, roughly flat from $13.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $14.1 million in Q3 2024 and bottomed at $779000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $12.8 million, with a median of $13.5 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets tumbled 94.23% in 2023, then skyrocketed 1705.13% in 2024.
  • Year by year, Other Non-Current Assets stood at $13.1 million in 2021, then rose by 3.02% to $13.5 million in 2022, then crashed by 94.23% to $779000.0 in 2023, then surged by 1705.13% to $14.1 million in 2024, then decreased by 2.64% to $13.7 million in 2025.
  • Business Quant data shows Other Non-Current Assets for PRME at $13.7 million in Q3 2025, $13.7 million in Q2 2025, and $14.1 million in Q1 2025.